A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma
Conclusion RX-3117 plus nab-Pac in newly diagnosed met-PC patients demonstrated tolerability, safety, and early treatment efficacy.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Drugs & Pharmacology | Investigational New Drugs | Oral Cancer | Pancreas | Pancreatic Cancer | Study | Toxicology